Development and validation of a method for the determination of folic acid in different pharmaceutical formulations using derivative spectrophotometry by Ribeiro, Marcos Vinícius de Moura et al.
*Correspondence: M. V. M. Ribeiro. Instituto de Química. Universidade Es-
tadual Paulista – UNESP. Rua Prof. Francisco Degni 55 - Jardim Quitandinha - 
14800-060 – Araraquara - SP, Brasil. E-mail: marcosvinicius1703@hotmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 52, n. 4, oct./dec., 2016
http://dx.doi.org/10.1590/S1984-82502016000400019
Development and validation of a method for the determination of 
folic acid in different pharmaceutical formulations using derivative 
spectrophotometry
Marcos Vinícius de Moura Ribeiro1,2,*, Ingrid da Silva Melo2, Francisco das Chagas da Costa 
Lopes2, Graziella Ciaramella Moita2
1Institute of Chemistry, São Paulo State University “Júlio de Mesquita Filho”, UNESP, Araraquara, SP, Brazil,  
2Department of Chemistry, Natural Science Center, Federal University of Piauí, Teresina, PI, Brazil
Folic acid is a B complex water-soluble vitamin that is essential to humans, and its deficiency can cause 
problems including congenital malformations in the fetus as well as heart disease. Most countries affected 
by diseases associated with a lack of folic acid now supplement foods with the vitamin. There is therefore 
a need for the development of new analytical procedures able to determine folic acid present in different 
matrices. This work describes the development of zero order and first order derivative spectrophotometric 
methods for the determination of folic acid in different pharmaceutical formulations, using 0.1 mol L-1 
NaOH as solvent. The methods are shown to be simple, selective, and robust. Good linearity was achieved, 
with correction coefficients ≥0.9996 and limits of detection and quantification ranging from 0.64 to 0.75 
and from 1.80 to 2.85 mg L-1, respectively. Recoveries of 98-104% were obtained in accuracy tests, and 
precision (as RSD) was between 0.2 and 4.8%. The methods can be used in routine analyses for quality 
control purposes, offering an alternative to the procedures already reported in the literature.
Uniterms: Folic acid/pharmaceutical formulations. Folic acid/pharmaceutical formulations/validation 
method. Folic acid/formulations/derivative spectrophotometry.
INTRODUCTION
Vitamins are a group of compounds essential for 
the normal development and growth of living beings. 
Folic acid (FA) and folates, which are different chemical 
forms of vitamin B9, belong to the water-soluble B-group 
vitamins (Zare, Shishehbore, Nematollahi, 2011; 
Catharino, Godoy, Lima-Pallone, 2006; Nasser et al., 
2005). Folate is a generic term for compounds possessing 
vitamin activity similar to that of pteroylglutamic acid, 
and is the form of the vitamin naturally present in foods 
(Krishnaswamy, Nair, 2001). Folic acid is a synthetic form 
of folate, found in vitamin supplements and fortified foods 
(Bailey, 2000). The main dietary sources of folic acid are 
spinach, white beans, asparagus, dark-leaved vegetables, 
Brussels sprouts, soybean and its derivatives, oranges, and 
melons, amongst others (Nasser et al., 2005; Deconinck 
et al., 2011). An important feature of vitamins is that they 
are generally not synthesized by mammalian cells and 
must therefore be supplied in sufficient amounts in the diet 
(Aurora-Prado et al., 2004).
At present, vitamin deficiency results mainly 
from poverty, food preferences, drug use, and chronic 
alcoholism, amongst other causes. If vitamin intake is 
insufficient, multivitamin preparations can be used in 
order to prevent vitamin deficiency and the associated 
physiological problems (Deconinck et al., 2011; Aurora-
Prado et al., 2004).
The chemical name of FA is N-[4-[[(2-amino-3,4-
dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-
L-glutamic acid (Deconinck et al., 2011; Flores et al., 
2005; Nagaraja, Vasantha, Yathirajan, 2002). Its structure 
is shown in Figure 1. It is essential for the formation 
of red blood cells and is important for growth and the 
prevention of anemia (Zhao et al., 2006). FA deficiency 
can lead to congenital malformations in the fetus (spina 
bifida, encephalocele, cleft palate, and hydrocephalus), 
as well as heart disease (Crane et al., 1995; Czeize, 
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Dudas, 1992; Oakley, Erickson, Adams, 1995; Santos, 
Pereira, 2007).
To date, FA is the most important risk factor 
identified for neural tube defects (Santos, Pereira, 2007). 
The severity of these defects means that it is important 
to undertake genetic counseling, supplement diets with 
folic acid, and perform prenatal diagnosis of neural tube 
defects (Pacheco et al., 2009). FA is required for normal 
growth, reproduction (during gestation and lactation), 
and antibody formation. It acts as a coenzyme in the 
metabolism of amino acids (glycine) and the synthesis 
of purines, pyrimidines, DNA, and RNA, and is vital for 
cell division and protein synthesis. Its deficiency can alter 
DNA synthesis and induce chromosomal changes (Santos, 
Pereira, 2007).
Folic acid is nontoxic, although there is some concern 
that high doses may mask pernicious anemia. This effect is 
only likely following ingestion of quantities greater than 
5 mg. Medicines containing levels of folic acid above 
the recommended values can be harmful to consumers 
(Cozzolino, 2009). There is therefore a continuing 
need for the development of new analytical procedures 
for the determination of FA present in pharmaceutical 
formulations (Zhao et al., 2006). In most countries affected 
by FA deficiency, foods are supplemented with the vitamin 
(Catharino, Godoy, 2001; Catharino, Visentainer, Godoy, 
2003; Caselunghe, Lindeberg, 2000). 
According to the Brazilian Pharmacopoeia (ANVISA, 
2010), high performance liquid chromatography (HPLC) 
is recommended for the identification and quantification 
of FA in pharmaceutical formulations. Although HPLC 
is a well-established technology in the pharmaceutical 
field, offering sensitivity and specificity, its disadvantages 
include high operating costs, the need for large amounts 
of samples and solvents, and the generation of hazardous 
wastes such as organic solvents that are expensive to 
dispose of and can have significant environmental impacts 
(Deconinck et al., 2011).
Methods reported in the l i terature for  the 
determination of folic acid include HPLC with different 
detectors (Aurora-Prado et al., 2004; Nelson, Sharpless, 
Sander, 2006; Chaudhary, Wang, Prabhu, 2010), 
electrophoresis (Zhao et al., 2006), electrochemical 
methods (Vaze, Srivastava, 2007; Prasad et al., 2010; 
Ensafi, Karimi-Maleh, 2010), flow injection analysis (Nie, 
He, Lu, 2000), and spectrophotometric methods (Pesce, 
Bodourian, 1986; Rao, Kanjilal, Mohan, 1978). The use of 
flow injection analysis and zero order spectrophotometry 
is problematic for the determination of folic acid in 
complex samples containing large amounts of interferents, 
because both techniques require prior extraction of the 
analyte, hence increasing the costs of routine analysis. 
However, the use of derivative spectrophotometry offers 
a simple and inexpensive solution for the determination 
of drugs in pharmaceutical formulations (Rêgo, Moura, 
Moita, 2010; Moura, Moita, 2012).
Derivative spectrophotometry has been widely used 
as a tool for the quality control of medicines, enabling 
the simultaneous determination of different drugs in 
multicomponent media. Derivation of the spectra enables 
the separation of superimposed signals and eliminates the 
background signal caused by the presence of other species 
in the sample. This technique can improve sensitivity and 
selectivity in the analysis of mixtures. Furthermore, it is 
accessible to most laboratories, since the procedure is 
simple, fast, and does not require prior extraction of the 
analyte from the sample (Donato et al., 2010; Vidotti, 
Rollemberg, 2006).
According to the criteria of the Brazilian National 
Health Surveillance Agency (ANVISA, 2003), a method 
must be validated experimentally in order to ensure that 
it meets the requirements of the analytical applications, 
hence ensuring the reliability of the results. The parameters 
considered include specificity, linear range, precision, 
sensitivity, quantification limit, and accuracy (ICH, 2000; 
INMETRO, 2011). The objective of the present work 
was therefore to develop and validate a method for the 
quantification of folic acid in pharmaceutical formulations 
by derivative spectrophotometry, comparing the technique 
to existing methods described in the literature.
MATERIAL AND METHODS
Reagents
Standards and pharmaceuticals
A reference standard of folic acid (99.77%) was 
FIGURE 1 - Structure of the folic acid molecule.
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obtained from Pharmanostra®. Samples of folic acid 
were studied in the form of tablets (5 mg) (Folacin®, 
lot #12097614), solution (400 mg L-1) (Folacin®, lot 
#1106225), and capsules (5 mg) (lot #019239). The 
samples were purchased in drugstores and prescription 
pharmacies.
Evaluation of interferents employed excipients used 
in commercial pharmaceutical formulations. These were: 
lactose (Pharmanostra®), talc (Henrifarma®), magnesium 
stearate (Valdequímica®), microcrystalline cellulose 
(Pharmanostra®), silicon dioxide (Henrifarma®), titanium 
dioxide (Deg®), methylparaben (Fagron®), propylparaben 
(Pharmanostra®), and ascorbic acid (Impex).
Reagents
Evaluation of the solvents used employed three 
different brands of sodium hydroxide (Synth, 97.0%; 
Impex, 99.0%; and Vetec, 99.0%), sodium carbonate 
(Dinâmica, 99.5%), and hydrochloric acid (Merck, 
37.0%). The solvent solutions were prepared using 
deionized water. All reagents used were analytical grade.
Instrumentation and treatment of the data
The spectrophotometric analyses were performed 
with a double beam Hitachi U-3000 spectrophotometer 
fitted with deuterium and tungsten lamps, using a scan 
range of 190-750 nm, scan speed of 300 nm min-1, and slit 
width of 2.0 nm. Quartz cuvettes with optical path length 
of 1 cm were used. The samples were centrifuged using a 
New Instrument NI 1812 centrifuge. Mass measurements 
were made with a Denver Instrument APX 200 analytical 
balance.
Origin 7.5 software (OriginLab) was used for 
statistical treatment of the data and the construction of 
graphs. Derivation of the spectra was performed with 
Hitachi UV00 spectrophotometry software.
Analytical validation
Robustness
The robustness of the method was evaluated using 
the following parameters: stability of the folic acid 
solutions, brand of sodium hydroxide, and concentration 
of the solvent.
For evaluation of the stability of the solutions, 
stock solutions of 100 mg L-1 folic acid were prepared in 
0.1 mol L-1 sodium hydroxide and 0.27 mol L-1 sodium 
carbonate. The stock solutions were divided into three 
250 mL flasks, one of which was transparent (allowing 
the passage of light) and the others amber (preventing the 
entry of light). The solution contained in the transparent 
bottle was kept on the laboratory bench and was exposed 
to ambient light during the daytime, and the others were 
wrapped in aluminum foil. One of the two solutions 
that were protected from light was kept at an average 
ambient temperature of 27.0 ± 4.0 °C, while the other was 
refrigerated at an average temperature of 3.0 ± 2.0 °C. For 
the analyses, the stock solutions were diluted to 10 mg L-1 
and spectra were acquired daily during a period of 4 days, 
and subsequently every 5 days up to 30 days. The analysis 
of variance (ANOVA, p = 0.05) was used to evaluate the 
data obtained at the wavelength of maximum absorption, 
in the range studied, and at a further 14 points located 
around λmax.
The study of different brands of sodium hydroxide 
was carried out using solutions of 10 mg L-1 folic acid in 
0.1 mol L-1 solutions of sodium hydroxide obtained from 
the different manufacturers (Synth, Vetec, and Impex). 
All spectra were acquired in triplicate and the analysis of 
variance (ANOVA, p = 0.05) was used to evaluate the data 
obtained at the wavelength of maximum absorption and at 
a further 14 points located around λmax.
The influence of the solvent concentration was 
evaluated using solutions of 10 mg L-1 folic acid in 
different concentrations of sodium hydroxide: 0.05, 0.1, 
and 0.2 mol L-1. All solutions were prepared in triplicate 
and then submitted to spectrophotometric analysis. The 
results were evaluated using the analysis of variance 
(ANOVA, p = 0.05), as described above. 
Linearity
Analytical curves were constructed using six folic 
acid concentrations between 5 and 50 mg L-1, prepared 
from a stock 100 mg L-1 solution. Spectral scanning of 
the solutions was then performed to obtain the zero order 
spectra. The 1st, 2nd, 3rd, and 4th order derivatives of the 
spectra were obtained, with Δλ varied between 1 and 10 
nm, using the UV00 spectrophotometer software.
Detection and quantification limits
The limits of detection and quantification were 
calculated using the expressions LOD = 3 s/a and LOQ = 
10 s/a, respectively, where s is the standard deviation of 
the blank signal and a is the slope (or angular coefficient) 
of the calibration curve (Moura, Moita, 2012). These 
calculations were performed using 21 blank spectra.
Selectivity
The selectivity of the method was assessed by 
analysis of the spectra of the excipients used in the 
pharmaceutical products prepared as tablets, capsules, 
and solution. The excipients were: lactose (50 to 250 mg 
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L-1), talc (50 to 250 mg L-1), magnesium stearate (50 to 
250 mg L-1), microcrystalline cellulose (50 to 250 mg L-1), 
silicon dioxide (50 to 250 mg L-1), titanium dioxide (50 to 
150 mg L-1), methylparaben (10 mg L-1), propylparaben 
(10 mg L-1), and ascorbic acid (100 mg L-1). The spectra 
obtained were compared with the spectrum of a 10 mg L-1 
folic acid standard solution.
Accuracy
Accuracy was assessed by addition and recovery 
tests using standards at three concentration levels (50, 
100, and 150%). In the case of the Folacin® solution, a 
100 mg L-1 standard solution of folic acid was prepared, 
and 0.5, 1.0, and 1.5 mL aliquots were transferred to three 
10 mL volumetric flasks. The drug solution was then 
used to prepare a solution containing 200 mg L-1 of folic 
acid, and 0.5 mL aliquots were transferred to the flasks 
containing the folic acid standard solutions, prepared 
previously. The volumes were then completed with the 
solvent, resulting in final concentrations of 0, 5.0, 10.0, and 
15.0 mg L-1 of folic acid standard and 10 mg L-1 of folic acid 
from the drug sample. All the procedures were performed 
in triplicate, using 0.1 mol L-1 NaOH as the solvent.
For the Folacin® tablet product, five tablets were 
crushed, and masses corresponding to 2.5 mg of folic 
acid were weighed out and transferred quantitatively to 
four 25 mL volumetric flasks, followed by addition of 
2.5, 5.0, and 7.5 mL aliquots of a 500 mg L-1 folic acid 
standard solution. The volumes were then completed with 
the solvent, and the samples were centrifuged for 30 min at 
3500 rpm, and then filtered with a quantitative filter paper 
to remove suspended material. Finally, 1 mL aliquots of 
each solution were transferred to 10 mL volumetric flasks 
and the volumes were completed with 0.1 mol L-1 NaOH to 
give final concentrations of 0, 5.0, 10.0, and 15.0 mg L-1 of 
standard and 10 mg L-1 of folic acid from the sample. These 
solutions were prepared in triplicate, and the accuracy was 
expressed in terms of the percentage recovery. The same 
procedure was used for the capsule form of the drug.
Precision
Evaluation was made of intra-day and inter-day 
precision. The drug samples were used to prepare 100 
mg L-1 folic acid solutions, in triplicate. In the case of the 
tablet and capsule samples, the solutions were centrifuged 
for 30 min at 3500 rpm, and then filtered with quantitative 
filter paper to remove suspended material. The solutions 
were diluted to 10 mL in volumetric flasks to obtain (in 
triplicate) folic acid concentrations of 15.0, 25.0, and 35.0 
mg L-1. The results obtained were expressed in terms of 
relative standard deviations (RSD).
RESULTS AND DISCUSSION
According to the Brazilian Pharmacopoeia 
(BRASIL, 2010), folic acid is insoluble in water 
and organic solvents, but exhibits good solubility in 
hydroxides, carbonates, and hot hydrochloric acid. The 
literature reports methods using sodium hydroxide and 
sodium carbonate as solvents, with folic acid showing 
good solubility under these conditions (Flores et al., 
2005; Zhao et al., 2006). This is due to reaction of the 
bases with the carboxylic groups present in the folic 
acid structure (Figure 1), resulting in the formation of 
carboxylic salts that are highly soluble in aqueous media. 
Under these conditions, the spectrum of the folic acid 
solution showed three well-defined bands of maximum 
absorption, at wavelengths of 255.5, 283.0, and 365.5 nm 
(Figure 2). In the case of hydrochloric acid, a low 
intensity band was observed and poor dissolution was 
achieved using acid concentrations of 1.0 and 3.0 mol L-1.
Robustness of the method
Stability
The stability tests showed that in the presence of 
sodium hydroxide, the standard solution of folic acid was 
stable for up to 28 days at ambient temperature, in both 
the presence and absence of light (Figures 3 and 4). The 
analysis of variance (ANOVA, p = 0.05) performed for the 
wavelength range around λmax showed that the absorbances 
were statistically the same during this period. The same 
behavior was observed for the refrigerated samples.
In the case of the standard solutions of folic acid 
in the presence of sodium carbonate, there was a marked 
FIGURE 2 - Spectra obtained for 10 mg L-1 folic acid in the 
presence of different solvents.
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decrease in the absorbance value at a wavelength of 
255.5 nm (Figure 3), which was due to photochemical 
degradation of the solution in the presence of light. This 
was also indicated by a progressive change in the color of 
the standard solution, from light yellow to dark yellow. 
In the absence of light, the behavior was similar to that 
observed using sodium hydroxide (Figure 4). These results 
were in agreement with the findings of other studies using 
HPLC (Catharino, Godoy, 2001; Catharino, Visentainer, 
Godoy, 2003). Sodium hydroxide was therefore selected 
as the solvent in subsequent experiments.
Influence of brand of sodium hydroxide
Evaluation of the folic acid spectra obtained using 
the different brands of sodium hydroxide showed that 
there was no significant difference (paired t-test, p = 0.05) 
between the measured absorbances for the Impex and 
Vetec brands, which could be explained by the fact that the 
degree of purity was 99.0% in both cases. However, when 
these spectra were compared with those obtained using 
sodium hydroxide from Synth, there was a difference in 
absorbance (ANOVA, p = 0.05), due to the lower degree 
of purity (97.0%) of the latter.
Influence of solvent concentration 
No significant differences (ANOVA, p = 0.05) 
were observed between the folic acid absorbance spectra 
acquired for the samples with three different concentrations 
of sodium hydroxide (0.05, 0.1, and 0.2 mol L-1). Since 
folic acid dissolved more rapidly in the presence of a 
higher concentration of the base, it was decided to use 0.1 
mol L-1 sodium hydroxide, which provided good stability 
of the standard solution and lower consumption of the 
reagent, compared to use of the 0.2 mol L-1 solution.
Evaluation of selectivity
The excipients used in the preparation of the 
capsules and tablets showed poor solubility in the solvent 
used. Talc was easily precipitated, while titanium dioxide 
and magnesium stearate remained in suspension. At 
higher concentrations, the turbidity of the suspensions 
increased, resulting in higher analytical signals 
throughout the entire spectrum, due to scattering of the 
radiation. This interference could affect the precision and 
accuracy of the method, and was therefore avoided using 
centrifugation and filtration. The excipients were tested at 
different concentrations, because the manufacturers did 
not provide any information concerning the quantities 
used.
In the case of the excipients used in the solution 
formulation, there was superimposition of the zero order 
folic acid spectrum and the excipient spectra, because 
the absorbance maxima of the latter were very close 
to that of folic acid, which hindered its determination 
(Figure 5). The zero crossing technique was therefore 
used to eliminate this interference (Moura, Moita, 
2012). The spectra of folic acid and the excipients were 
evaluated using four derivative orders and ten different 
Δλ. A significant folic acid signal was only obtained at a 
wavelength of 393.0 nm for the first derivative (D1) and 
for Δλ8, Δλ9, and Δλ10, with the excipients showing zero 
signals (Figure 6).
FIGURE 4 - Stability of 10 mg L-1 folic acid solutions in the 
absence of light, using 0.1 mol L-1 Na2CO3 (255.5 nm (1), 
283.0 nm (2), 365.5 nm (3)) and 0.1 mol L-1 NaOH (255.5 nm (4), 
283.0 nm (5), 365.5 nm (6)).
FIGURE 3 - Stability of 10 mg L-1 folic acid solutions in the 
presence of light, using 0.27 mol L-1 Na2CO3 (255.5 nm (1), 
283.0 nm (2), 365.5 nm (3)) and 0.1 mol L-1 NaOH (255.5 nm 
(4), 283.0 nm (5), 365.5 nm (6)).
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Linearity and limits of detection and 
quantification
Table I shows the parameters of the calibration 
curves obtained for standard solutions of folic acid in 0.1 
mol L-1 sodium hydroxide. The curves presented good 
slopes, intercepts near zero, and correlation coefficients 
that exceeded the values recommended by ANVISA (2003) 
(r = 0.99) and INMETRO (2011) (r = 0.9). The detection 
and quantification limits were in the ranges 0.64-0.85 and 
1.80-2.85 mg L-1, respectively, and were lower than the 
lowest concentration in the solutions analyzed (5 mg L-1). 
The developed method therefore provided satisfactory 
sensitivity and linearity. The results were similar to those 
obtained previously using chromatographic (Aurora-
Prado et al., 2004; Zhao et al., 2006; Nelson, Sharpless, 
Sander, 2006) and electrochemical techniques (Zare, 
Shishehbore, Nematollahi, 2011; Vaze, Srivastava, 2007; 
Ensafi, Karimi-Maleh, 2010) for the analysis of folic acid 
in different matrices.
Evaluation was made of differences in the analytical 
parameters at different Δλ, using the wavelength of 393.0 
nm (D1), since in the case of the Folacin® solution, only 
the first derivative gave satisfactory results. It can be seen 
from the data provided in Table I that the results obtained 
for Δλ10 were similar to those found for Δλ8 and Δλ9, with 
only slight differences, since the increase of Δλ provided 
better signal resolution by decreasing the noise present in 
the spectrum.
Accuracy of the method
The results of the accuracy tests (Table II), performed 
in triplicate using three concentration levels, showed that 
in most cases the recoveries ranged from 98 to 105%, 
within the limits established by ANVISA (80-120%). In 
FIGURE 6 - Comparison of Δλ10 first derivative spectra for 
10 mg L-1 folic acid and the main excipients used in the solution 
formulation.
FIGURE 5 - Comparison of zero order spectra for 10 mg L-1 folic 
acid and the main excipients used in the solution formulation.
TABLE I - Analytical parameters for the quantification of folic acid
Method λ (nm) Linear equation r LOD (mg L-1) LOQ (mg L-1) LOL (mg L-1)
ZO 255.5 A=0.041+0.054C 0.9996 0.75 2.51 50
ZO 283.0 A=0.035+0.053C 0.9996 0.81 2.71 50
ZO 365.5 A=0.020+0.019C 0.9988 0.85 2.85 50
D1 (∆λ8) 393.0 D1=-0.004-0.032C 0.9998 0.67 1.80 50
D1 (∆λ9) 393.0 D1=-0.005-0.034C 0.9998 0.65 1.80 50
D1 (∆λ10) 393.0 D1=-0.005-0.035C 0.9998 0.64 1.78 50
ZO - Zero order, D1 - First order derivative, LOD - Limit of detection, LOQ - Limit of quantification, LOL - Limit of linearity, 
r - linear correlation coefficient.
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tests with the Folacin® solution, the values obtained using 
the ZO method (365.5 nm) were in the range 90-94%, with 
RSD of up to 10.3%, due to the spectral overlap associated 
with the excipients used in the formulation (Figure 5). 
This difficulty was resolved using method D1 (393.0 nm) 
at different Δλ, resulting in recovery values in the range 
100-104% (Table II).
Similar recoveries were obtained in previous studies 
using HPLC (94.3-105.8% and ≥95%) (Zhao et al., 
2006; Nelson, Sharpless, Sander, 2006), electrochemical 
methods (97.7-103.6%) (Beitollahi, Sheikhshoaie, 2011), 
and flow injection analysis (>95.3%) (Nie, He, Lu, 
2000).
Precision of the method
Intra-day and inter-day precisions (Table III) were 
determined using three concentration levels. The data 
showed that the method provided high levels of precision 
when used by the same analyst on the same day and by 
TABLE II – Results of accuracy tests for the samples at three concentration levels
Formulation Method  
(λ, nm)
Added 
(mg L-1)
Recovered 
(mg L-1)
Recovery 
(%)
RSD 
(%)
Folacin® 
(solution)
ZO 
(365.5)
5.0 4.5 90 3.9
10.0 9.4 94 10.3
15.0 13.9 92 7.2
D1 
(393.0) 
∆λ10
5.0 4.9 98 3.1
10.0 10.5 105 0.5
15.0 15.2 101 2.0
D1 
(393.0) 
∆λ9
5.0 5.2 103 2.2
10.0 10.5 105 3.2
15.0 15.5 103 1.9
D1 
(393.0) 
∆λ8
5.0 5.0 100 3.5
10.0 10.4 104 3.2
15.0 15.3 102 2.0
Folacin® 
(tablet)
ZO 
(255.5)
5.0 5.1 103 4.8
10.0 10.2 102 2.4
15.0 15.0 100 1.2
ZO 
(283.0)
5.0 5.1 102 4.9
10.0 10.1 101 2.5
15.0 14.9 99 1.4
ZO 
(365.5)
5.0 5.0 100 5.0
10.0 10.0 100 2.6
15.0 14.7 98 2.6
D1 
(393.0) 
∆λ10
5.0 5.1 102 4.4
10.0 10.1 101 1.6
15.0 15.0 100 0.5
Capsules ZO 
(255.5)
5.0 5.1 102 0.7
10.0 10.4 104 1.5
15.0 14.7 98 0.4
ZO 
(283.0)
5.0 5.0 100 1.2
10.0 10.4 104 1.5
15.0 14.7 98 0.3
ZO 
(365.5)
5.0 5.0 101 2.7
10.0 10.4 104 1.4
15.0 14.8 99 1.1
D1 
(393.0) 
∆λ10
5.0 5.2 104 1.2
10.0 10.4 104 1.0
15.0 14.7 98 0.9
ZO - Zero order, D1 - First order derivative, RSD - Relative standard deviation
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different analysts on different days, with RSD values 
ranging from 0.2 to 4.8%, which were lower than the 
maximum allowed by ANVISA (5.0%). The lowest values 
were found for method D1 (393.0 nm), showing that use 
of the derivative improved the signal and eliminated 
interference.
The intra- and inter-day precisions were assessed by 
application of the F-test and the paired t-test (p = 0.05). 
The results revealed that for the three concentration levels 
studied, there were no statistically significant differences 
between the results obtained.
CONCLUSIONS
The methods developed for the determination of 
folic acid in pharmaceutical formulations were shown 
to be simple, selective, and robust in terms of stability 
and the effects of different brands of sodium hydroxide 
TABLE III - Intra-day and inter-day precisions for the proposed methods
Formulation Method  
(λ, nm)
Concentration 
level 
(mg L-1)
Intra-day precision Inter-day precision
RSD 
(%)
RSD  
(%)
RSD  
(%)
Folacin® 
(solution)
ZO 
(365.5)
15.0 1.3 4.7 4.1
25.0 1.5 1.6 1.8
35.0 4.3 0.4 2.7
D1 
(393.0) 
∆λ10
15.0 1.0 3.8 4.4
25.0 0.4 2.4 0.5
35.0 4.0 0.9 2.4
D1 
(393.0) 
∆λ9
15.0 1.9 4.3 4.7
25.0 0.5 2.2 0.6
35.0 3.4 0.8 1.1
D1 
(393.0) 
∆λ8
15.0 1.2 4.6 3.9
25.0 1.0 2.2 0.8
35.0 2.5 0.8 0.3
Folacin® 
(tablet)
ZO 
(255.5)
15.0 1.7 0.3 4.0
25.0 1.3 0.6 0.8
35.0 1.4 0.1 1.5
ZO 
(283.0)
15.0 1.6 0.2 4.1
25.0 1.4 0.5 0.9
35.0 1.3 0.1 1.5
ZO 
(365.5)
15.0 2.3 0.9 4.8
25.0 1.8 1.6 2.5
35.0 1.1 0.4 2.3
D1 
(393.0) 
∆λ10
15.0 1.5 0.6 3.8
25.0 1.3 0.7 0.2
35.0 1.5 0.1 0.7
Capsules ZO 
(255.5)
15.0 1.4 0.9 1.4
25.0 2.5 1.4 2.6
35.0 1.2 1.7 2.7
ZO 
(283.0)
15.0 1.2 0.7 1.4
25.0 2.4 1.5 2.6
35.0 1.2 1.7 2.7
ZO 
(365.5)
15.0 1.8 1.5 1.3
25.0 2.6 1.1 2.5
35.0 1.3 1.9 2.6
D1 
(393.0) 
∆λ10
15.0 1.0 0.4 1.6
25.0 2.3 1.6 2.9
35.0 1.1 1.4 2.6
ZO - Zero order, D1 - First order derivative, RSD - Relative standard deviation.
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and different solvent concentrations. Good linearity was 
achieved in the concentration range studied, together 
with satisfactory accuracy and precision. The proposed 
methods offer an alternative for use in the quality control 
of pharmaceutical formulations, being less complex and 
requiring smaller amounts of toxic reagents, compared 
to HPLC.
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